Sensei Biotherapeutics (FTH) Projected to Release Quarterly Earnings on Tuesday

Sensei Biotherapeutics (NASDAQ:FTH) is expected to issue its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Sensei Biotherapeutics to announce earnings of ($5.0450) per share for the quarter. Individuals can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 9:30 AM ET.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter. On average, analysts expect Sensei Biotherapeutics to post $-17 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Sensei Biotherapeutics Price Performance

Sensei Biotherapeutics stock opened at $27.24 on Monday. The stock has a market capitalization of $36.50 million, a price-to-earnings ratio of -0.19 and a beta of -0.25. Sensei Biotherapeutics has a one year low of $7.10 and a one year high of $37.90.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on FTH. Citigroup assumed coverage on shares of Sensei Biotherapeutics in a report on Friday, May 22nd. They set a “buy” rating and a $55.00 price objective on the stock. Oppenheimer initiated coverage on shares of Sensei Biotherapeutics in a research note on Tuesday, July 28th. They issued an “outperform” rating and a $60.00 target price for the company. Weiss Ratings assumed coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. Leerink Partners assumed coverage on shares of Sensei Biotherapeutics in a research note on Monday, April 20th. They set an “outperform” rating and a $50.00 price target on the stock. Finally, Wall Street Zen cut shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Sensei Biotherapeutics has an average rating of “Moderate Buy” and an average price target of $54.89.

Insider Activity

In other news, CEO Anand Kiran Parikh acquired 2,806 shares of Sensei Biotherapeutics stock in a transaction dated Monday, June 22nd. The stock was purchased at an average cost of $19.76 per share, for a total transaction of $55,446.56. Following the completion of the purchase, the chief executive officer directly owned 764,234 shares in the company, valued at $15,101,263.84. This trade represents a 0.37% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Brian C. Stephenson acquired 9,391 shares of Sensei Biotherapeutics stock in a transaction dated Wednesday, June 24th. The stock was purchased at an average price of $26.13 per share, with a total value of $245,386.83. Following the completion of the purchase, the chief financial officer owned 26,804 shares of the company’s stock, valued at approximately $700,388.52. The trade was a 53.93% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have bought 49,494 shares of company stock valued at $1,188,822. Company insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC raised its holdings in shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH) by 10.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,516 shares of the company’s stock after acquiring an additional 1,100 shares during the period. Renaissance Technologies LLC owned approximately 0.91% of Sensei Biotherapeutics worth $123,000 at the end of the most recent quarter. 10.50% of the stock is owned by hedge funds and other institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.